JSAM
STOK icon

J. Safra Asset Management’s Stoke Therapeutics STOK Stock Holding History

J. Safra Asset Management’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.08K Sell
247
-52
-17% -$1.67K ﹤0.01% 426
2026
Q1 		$9.73K Buy
299
+202
+208% +$6.63K ﹤0.01% 378
2025
Q4 		$3.08K Sell
97
-37
-28% -$1.11K ﹤0.01% 495
2025
Q3 		$3.15K Buy
+134
New +$2.3K ﹤0.01% 347

Other funds holding STOK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

J. Safra Asset Management's STOK Position: Q2 2026 in Review

J. Safra Asset Management reduced its Stoke Therapeutics (STOK) stake by 17% in Q2 2026, selling an estimated $1.67K and leaving 247 shares worth $8.08K. The position accounts for ﹤0.01% of the portfolio, ranked #426.

J. Safra Asset Management first reported a position in STOK in Q3 2025 and has held it in 4 quarters since. The position peaked at $9.73K in Q1 2026. 197 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

  • J. Safra Asset Management held 247 shares of Stoke Therapeutics worth $8.08K as of Q2 2026.
  • J. Safra Asset Management sold 52 Stoke Therapeutics shares in Q2 2026, an estimated $1.67K.
  • Stoke Therapeutics made up ﹤0.01% of J. Safra Asset Management's portfolio in Q2 2026, its #426 holding.
  • J. Safra Asset Management first reported a position in Stoke Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • J. Safra Asset Management's Stoke Therapeutics position peaked at $9.73K in Q1 2026.
  • 197 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on J. Safra Asset Management's 13F filing for Q2 2026, filed 6 Aug 2026.